At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 32 target
Drug / intervention
SBRTradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Study of OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases
In Brief
A clinical study evaluating SBRT for Liver Metastases and 2 related conditions. Currently recruiting, targeting 32 participants across 1 site.
Detailed Summary
The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively. Eligible participants will be on study for up to 12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ARecruiting
2020202120222023202420252026202720282029
First PostedJul 2019
Enrollment StartNov 2019
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2028
First PostedJul 16, 2019
Enrollment StartNov 4, 2019
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2028
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 7.0 years agoPrimary completion in 5 months
Interventions
SBRTradiation
Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments.